Literature DB >> 18219772

Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects.

Hsien-Liang Huang1, Wen-Yuan Lin, Long-Teng Lee, Hsih-Hsi Wang, Wei-Jei Lee, Kuo-Chin Huang.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to steatohepatitis (NASH), have become important health issues in obese subjects. In this study, we investigated the relationship between MetS and NASH in severely obese subjects.
METHODS: A total of 111 non-alcoholic obese patients who underwent laparoscopic bariatric surgery (BMI 45.4 +/- 5.7 kg/m2) were enrolled from February to September 2004 in a referral center in North Taiwan. MetS and its individual components were defined using the American Heart Association/National Heart, Lung, and Blood Institute criteria. Based on liver biopsy during surgery, subjects were classified into either having NASH or not. The relationship among NASH, adiponectin, insulin resistance, MetS and its individual components was examined using a multivariate logistic regression analysis.
RESULTS: The prevalence of NASH and MetS in these subjects was 79.3% and 68.5%, respectively. Using a multivariate logistic regression analysis with NASH as the outcome variable, odds ratio (OR) of NASH for subjects with MetS versus without MetS was 2.96 (95% CI = 1.14-7.68) adjusted for age, gender, and BMI. Also, high blood pressure (OR = 2.97, 1.31-6.73) and high fasting glucose (OR = 2.94, 1.13-7.67) were independently associated with NASH after adjustment for age, gender, and BMI. Insulin resistance measured as HOMA-IR and serum adiponectin level were not significantly different between the NASH and non-NASH group.
CONCLUSION: MetS and NASH were common in severely obese Taiwanese adults. Presence of MetS, high blood pressure, and high fasting glucose was independently related to increased risk of NASH. The underlying mechanism deserves to be explored in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18219772     DOI: 10.1007/s11695-008-9423-0

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  43 in total

Review 1.  Medical consequences of obesity.

Authors:  George A Bray
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis.

Authors:  B F Banner; L Savas; J Zivny; K Tortorelli; H L Bonkovsky
Journal:  Am J Clin Pathol       Date:  2000-12       Impact factor: 2.493

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Authors:  Shiro Yokohama; Masashi Yoneda; Masakazu Haneda; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Yoshihiko Tokusashi; Naoyuki Miyokawa; Kimihide Nakamura
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

8.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

Authors:  Boris Hansel; Philippe Giral; Estelle Nobecourt; Sandrine Chantepie; Eric Bruckert; M John Chapman; Anatol Kontush
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

9.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

10.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

View more
  17 in total

1.  The relationship of plasma adiponectin with liver fibrosis in morbid obesity.

Authors:  Teoman Dogru; Nuri Karadurmus; Guldem Kilciler; Serkan Tapan; Cemal Nuri Ercin
Journal:  Obes Surg       Date:  2010-10       Impact factor: 4.129

2.  Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects.

Authors:  Cemal Nuri Ercin; Teoman Dogru; Ilker Tasci; Gokhan Erdem; Alper Sonmez
Journal:  Obes Surg       Date:  2008-06-19       Impact factor: 4.129

3.  Non-alcohol fatty liver disease in Asia: Prevention and planning.

Authors:  Sara Ashtari; Mohamad Amin Pourhoseingholi; Mohamad Reza Zali
Journal:  World J Hepatol       Date:  2015-07-08

4.  Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD).

Authors:  Ajay Duseja; Naga Chalasani
Journal:  Hepatol Int       Date:  2013-11-02       Impact factor: 6.047

5.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

6.  Dietary conjugated linoleic Acid and hepatic steatosis: species-specific effects on liver and adipose lipid metabolism and gene expression.

Authors:  Diwakar Vyas; Anil Kumar G Kadegowda; Richard A Erdman
Journal:  J Nutr Metab       Date:  2011-08-22

7.  Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.

Authors:  Craig D Fisher; Andrew J Lickteig; Lisa M Augustine; James Ranger-Moore; Jonathan P Jackson; Stephen S Ferguson; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2009-08-03       Impact factor: 3.922

8.  Hepatic angiogenesis and fibrosis are common features in morbidly obese patients.

Authors:  Monika Ciupińska-Kajor; Marek Hartleb; Maciej Kajor; Michał Kukla; Mariusz Wyleżoł; Dariusz Lange; Lukasz Liszka
Journal:  Hepatol Int       Date:  2011-11-29       Impact factor: 6.047

9.  An exploration of prevalence and associated factors of nonalcoholic Fatty liver disease in the taiwanese police service.

Authors:  Th Tung; Wh Chiu; Th Lin; Hc Shih; Ct Hsu
Journal:  Iran J Public Health       Date:  2011-12-31       Impact factor: 1.429

Review 10.  Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.

Authors:  Melania Gaggini; Mariangela Morelli; Emma Buzzigoli; Ralph A DeFronzo; Elisabetta Bugianesi; Amalia Gastaldelli
Journal:  Nutrients       Date:  2013-05-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.